Daratumumab, an anti-CD38 monoclonal antibody, which was studied and approved for the front-line treatment of multiple myeloma [60], has shown pre-clinical efficacy in T-ALL xenograft models [59,61]. The gene discussed is CD38; the disease is acute lymphoblastic leukemia.